NLS Pharmaceutics Ltd. (NASDAQ:NLSP) Short Interest Up 55.9% in December

NLS Pharmaceutics Ltd. (NASDAQ:NLSP) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 132,400 shares, a growth of 55.9% from the November 30th total of 84,900 shares. Based on an average daily trading volume, of 370,600 shares, the days-to-cover ratio is presently 0.4 days. Currently, 8.1% of the shares of the stock are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NLS Pharmaceutics stock. Armistice Capital LLC grew its stake in NLS Pharmaceutics Ltd. (NASDAQ:NLSP) by 6.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,311,000 shares of the company’s stock after acquiring an additional 139,000 shares during the period. Armistice Capital LLC owned 19.62% of NLS Pharmaceutics worth $501,000 as of its most recent filing with the Securities and Exchange Commission.

NLS Pharmaceutics Stock Performance

Shares of NASDAQ NLSP traded up $0.95 during mid-day trading on Monday, hitting $2.77. 20,529,165 shares of the stock were exchanged, compared to its average volume of 259,175. The stock’s fifty day simple moving average is $3.12 and its two-hundred day simple moving average is $1.75. NLS Pharmaceutics has a twelve month low of $1.73 and a twelve month high of $24.00.

NLS Pharmaceutics Company Profile

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD).